Sun recalls cancer drug

Share this article:

Sun Pharmaceuticals has racked up its second recall of the year. Reuters reports that the drugmaker has recalled 200 vials of the cancer drug gemcitabine which were distributed in the US. Reuters notes that the voluntary recall, which started in April, was in the “Class II” category which means potential adverse reactions would be temporary.

The generics maker, which recently purchased beleaguered Ranbaxy Pharmaceuticals, recalled 2,528 bottles of its generic Glumetza diabetes drug earlier this year after a patient found epilepsy medication in his bottle.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters